Clinical Study for Evaluating the Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration.
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 3
- 主要终点
- Number of participants with treatment-related adverse events codified using MedDRA.
研究概览
简要总结
The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with wet AMD.
详细描述
Age-related macular degeneration is the main cause of severe vision loss in patients over 65 years of age. There is solid evidence of the efficacy and safety of bevacizumab in the treatment of wet AMD. However, it has not been registered for such indication yet.
In response to the need for a proper adaptation, Lumiere® has been developed in a single-dose, sterile dosage containing bevacizumab 5 mg/vial in 0.2 mL injectable solution.
This adaptation is intended to assure intravitreal administration avoiding the risk of contamination and potential adverse consequences, such as endophthalmitis and blindness, associated to reutilization or repackaging of bevacizumab vials for oncological use.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients over 50 years of age diagnosed with wet age-related macular degeneration having indication of antiangiogenic therapy.
- •Both genders.
- •Subjects able to give informed consent.
排除标准
- •Patients with contraindication to receive bevacizumab:
- •Hypersensitivity to the active ingredient or to some of the formula excipients.
- •Hypersensitivity to products derived from CHO cells or to other human recombinant antibodies or humanized antibodies.
- •Patients having received intravitreal antiangiogenic therapy prior to wet AMD treatment.
- •Patients receiving previous systemic antiangiogenic therapy.
- •Wet AMD in the healing period or disciform scar.
- •Pregnant, breastfeeding or childbearing-aged women.
- •Any person with choroidal neovascularization not associated to wet AMD.
- •History of retinal or intraocular surgery in the affected eye in the last three months.
- •Vitrectomy in the affected eye.
- •Any significant ocular infection, active or suspected, having compromised or able to compromise the eye to be studied.
- •Ocular inflammatory disease.
- •Myopia exceeding -8 diopters.
- •Extensive subfoveal subretinal hemorrhage > 2 papillary diameter (PD).
- •Coexistence of other severe ocular diseases: uncontrolled ocular hypertension, terminal glaucoma, diabetic retinopathy, retinal vein thrombosis, optic atrophy.
- •History of stroke or myocardial infarction in the last 6 months.
- •Patients with coagulopathies.
- •Patients physically or mentally disabled to participate in such visual tests.
研究组 & 干预措施
Bevacizumab (Lumiere®)
Dosage form: intravitreal single dose vial. Dosage: 0.05ml (1.25 mg) Frequency: monthly injections (up to 6 doses)
干预措施: Bevacizumab (Lumiere®) (Drug)
结局指标
主要结局
Number of participants with treatment-related adverse events codified using MedDRA.
时间窗: 6 months
Register reports of drug related adverse events and compare them with prevalence in the literature after intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with neovascular AMD.
次要结局
- Number of participants with changes in visual acuity using the ETDRS charts in patients with wet AMD.(6 months)
- Number of participants with changes in retinal thickness as assessed by OCT in patients with wet AMD.(6 months)